Wary pharma: AstraZeneca sours on UK

After Iran appoints a new supreme leader, what does the choice tell us about the resilience of the regime and how the war will progress? Scientific research in America has taken a battering in Donald Trump’s second term. And why British choirs face a shortage of tenor voices.Gues ...  Show more

After a momentous week, our editors reflect on how uncertainty about the goals of the war in Iran will affect its course. Iran’s retaliation has been fierce and wide ranging. How long can Gulf stocks of missile interceptors last? And our obituaries editor looks back at the life o ...  Show more

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean a ...  Show more

America’s health secretary, RFK Jr, is known for his opposition to vaccines, particularly mRNA jabs, that have the potential to treat a large swathe of diseases. Slashing funding will have long term implications beyond America. Our correspondent visits Britain’s biggest and newes ...  Show more

With China as its new rival, America is reviving old wartime facilities across the Pacific. Our correspondent visits an abandoned airfield that has been given new life. The outlook for climate technology is surprisingly bright. And why the universe of Hello Kitty keeps expanding. ...  Show more

Since Donald Trump announced punishing tariffs on “Liberation Day” last week, stock markets have fallen and governments and businesses scrambled to respond. Our correspondent discusses the impact on the global economy. Do personalised diets really improve gut health (9:16)? And g ...  Show more